Table Info

Table 1.

Average alcohol consumption in studies investigating the impact of spirits, wine, and beer intake on the liver

Study	Alcohol consumption
Mitchell et al. [35]	20 g (2.3–60 g) alcohol/week
Tverdal et al. [36]	1.07–1.25 drinks/day (15.6–21.0 g alcohol)
Askgaard et al. [37]	14–28 drinks/week (168–336 g alcohol)
Hagström et al. [38]	5.1–24.6 g alcohol/day
Stokkeland et al. [39]	Alcoholic cirrhosis: 4.4 drinks/day (52.8 g alcohol/day) Alcohol dependence: 5.8 drinks/day (69.6 g alcohol/day)
Ye et al. [40]	7.95–10.94 L alcohol/capita per year
Jani et al. [42]	8–400 g alcohol/week

Declarations

Author contributions

FJ, VS, and AB: Investigation, Visualization, Writing—original draft, Writing—review & editing. IB: Conceptualization, Project administration, Supervision, Writing—original draft, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Funded in parts by grants from the Austrian Science Fund (FWF, [P-32164] to IB) and the Wissenschaftsförderung der Deutschen Brauwirtschaft e.V. (Wifö, [B115] to IB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

GBD 2020 Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet. 2022;400:185–235. Erratum in: Lancet. 2022;400:358. [DOI] [PubMed] [PMC]

Poznyak V, Rekve D, editors. Global status report on alcohol and health 2018 [Internet]. World Health Organization; c2018 [cited 2023 Apr 3]. Available from: https://www.who.int/publications/i/item/9789241565639

Zhang X, Zhang X, Liu M, Zhu L, He Z. Global, regional, and national burden of cirrhosis and other chronic liver diseases due to alcohol use, 1990–2019: a systematic analysis for the Global Burden of Disease study 2019. BMC Gastroenterol. 2022;22:484. [DOI] [PubMed] [PMC]

Osna NA, Kharbanda KK. Multi-organ alcohol-related damage: mechanisms and treatment. Biomolecules. 2016;6:20. [DOI] [PubMed] [PMC]

Szabo G, Kamath PS, Shah VH, Thursz M, Mathurin P, EASL-AASLD Joint Meeting. Alcohol-related liver disease: areas of consensus, unmet needs and opportunities for further study. Hepatology. 2019;69:2271–83. [DOI] [PubMed]

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154–81. [DOI] [PubMed]

Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken). 2021;17:365–70. [DOI] [PubMed] [PMC]

Taylor Richardson C, Singal AK. Epidemiology of alcoholic liver disease. In: Wong RJ, Gish RG, editors. Clinical epidemiology of chronic liver diseases. Cham: Springer International Publishing; 2019. pp. 75–98.

Subramaniam S. Understanding survival analyses. In: Wong RJ, Gish RG, editors. Clinical epidemiology of chronic liver diseases. Cham: Springer International Publishing; 2019. pp. 33–9.

10.

Axley PD, Richardson CT, Singal AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease. Clin Liver Dis. 2019;23:39–50. [DOI] [PubMed]

11.

Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37–49. [DOI] [PubMed] [PMC]

12.

Liu SY, Tsai IT, Hsu YC. Alcohol-related liver disease: basic mechanisms and clinical perspectives. Int J Mol Sci. 2021;22:5170. [DOI] [PubMed] [PMC]

13.

Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW, et al. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res. 2001;25:502–7. [DOI] [PubMed]

14.

Enoch MA. Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism. Pharmacol Biochem Behav. 2014;123:17–24. [DOI] [PubMed] [PMC]

15.

Li H, Borinskaya S, Yoshimura K, Kal’ina N, Marusin A, Stepanov VA, et al. Refined geographic distribution of the oriental ALDH2^*504Lys (nee 487Lys) variant. Ann Hum Genet. 2009;73:335–45. [DOI] [PubMed] [PMC]

16.

Higuchi S, Matsushita S, Masaki T, Yokoyama A, Kimura M, Suzuki G, et al. Influence of genetic variations of ethanol-metabolizing enzymes on phenotypes of alcohol-related disorders. Ann N Y Acad Sci. 2004;1025:472–80. [DOI] [PubMed]

17.

Thomasson HR, Edenberg HJ, Crabb DW, Mai XL, Jerome RE, Li TK, et al. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. Am J Hum Genet. 1991;48:677–81. [PubMed] [PMC]

18.

Nelson GH, Kinard FW, Hay MG. Rate of metabolism of ethanol in the mouse. Am J Physiol. 1957;190:169–71. [DOI] [PubMed]

19.

Hege M, Jung F, Sellmann C, Jin C, Ziegenhardt D, Hellerbrand C, et al. An iso-α-acid-rich extract from hops (Humulus lupulus) attenuates acute alcohol-induced liver steatosis in mice. Nutrition. 2018;45:68–75. [DOI] [PubMed]

20.

Landmann M, Sellmann C, Engstler AJ, Ziegenhardt D, Jung F, Brombach C, et al. Hops (Humulus lupulus) content in beer modulates effects of beer on the liver after acute ingestion in female mice. Alcohol Alcohol. 2017;52:48–55. [DOI] [PubMed]

21.

Osna NA, Rasineni K, Ganesan M, Donohue TM Jr, Kharbanda KK. Pathogenesis of alcohol-associated liver disease. J Clin Exp Hepatol. 2022;12:1492–513. [DOI] [PubMed]

22.

Jiang Y, Zhang T, Kusumanchi P, Han S, Yang Z, Liangpunsakul S. Alcohol metabolizing enzymes, microsomal ethanol oxidizing system, cytochrome P450 2E1, catalase, and aldehyde dehydrogenase in alcohol-associated liver disease. Biomedicines. 2020;8:50. [DOI] [PubMed] [PMC]

23.

Cederbaum AI. Alcohol metabolism. Clin Liver Dis. 2012;16:667–85. [DOI] [PubMed] [PMC]

24.

Aragon CMG, Rogan F, Amit Z. Ethanol metabolism in rat brain homogenates by a catalase-H₂O₂ system. Biochem Pharmacol. 1992;44:93–8. [DOI] [PubMed]

25.

Zakhari S, Li TK. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. Hepatology. 2007;46:2032–9. [DOI] [PubMed]

26.

Schnabl B. Liver capsule: mechanisms of alcoholic hepatitis. Hepatology. 2016;64:276. [DOI] [PubMed]

27.

Lieber CS, DeCarli LM. Ethanol oxidation by hepatic microsomes: adaptive increase after ethanol feeding. Science. 1968;162:917–8. [DOI] [PubMed]

28.

Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017;38:147–61. [PubMed] [PMC]

29.

Roberts BJ, Song BJ, Soh Y, Park SS, Shoaf SE. Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1 (*). J Biol Chem. 1995;270:29632–5. [DOI] [PubMed]

30.

Wang X, Lu Y, Xie B, Cederbaum AI. Chronic ethanol feeding potentiates Fas Jo2-induced hepatotoxicity: role of CYP2E1 and TNF-α and activation of JNK and P38 MAP kinase. Free Radic Biol Med. 2009;47:518–28. [DOI] [PubMed] [PMC]

31.

Rehm J, Hasan OSM. Is burden of disease differentially linked to spirits? A systematic scoping review and implications for alcohol policy. Alcohol. 2020;82:1–10. [DOI] [PubMed]

32.

GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392:1015–35. Erratum in: Lancet. 2018;392:1116. Erratum in: Lancet. 2019;393:e44. [DOI] [PubMed] [PMC]

33.

Stockwell T, Zhao J, Panwar S, Roemer A, Naimi T, Chikritzhs T. Do “moderate” drinkers have reduced mortality risk? A Systematic review and meta-analysis of alcohol consumption and all-cause mortality. J Stud Alcohol Drugs. 2016;77:185–98. [DOI] [PubMed] [PMC]

34.

Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671. [DOI] [PubMed] [PMC]

35.

Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, et al. Type and pattern of alcohol consumption is associated with liver fibrosis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol. 2018;113:1484–93. [DOI] [PubMed]

36.

Tverdal A, Skurtveit S, Selmer R, Myhre R, Thelle D. Coffee and wine consumption is associated with reduced mortality from alcoholic liver disease: follow-up of 219,279 Norwegian men and women aged 30–67 years. Ann Epidemiol. 2018;28:753–8. [DOI] [PubMed]

37.

Askgaard G, Grønbæk M, Kjær MS, Tjønneland A, Tolstrup JS. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol. 2015;62:1061–7. [DOI] [PubMed]

38.

Hagström H, Hemmingsson T, Discacciati A, Andreasson A. Risk behaviors associated with alcohol consumption predict future severe liver disease. Dig Dis Sci. 2019;64:2014–23. [DOI] [PubMed] [PMC]

39.

Stokkeland K, Hilm G, Spak F, Franck J, Hultcrantz R. Different drinking patterns for women and men with alcohol dependence with and without alcoholic cirrhosis. Alcohol Alcohol. 2008;43:39–45. [DOI] [PubMed]

40.

Ye Y, Kerr WC. Alcohol and liver cirrhosis mortality in the United States: comparison of methods for the analyses of time-series panel data models. Alcohol Clin Exp Res. 2011;35:108–15. [DOI] [PubMed] [PMC]

41.

Kerr WC, Fillmore KM, Marvy P. Beverage-specific alcohol consumption and cirrhosis mortality in a group of English-speaking beer-drinking countries. Addiction. 2000;95:339–46. [DOI] [PubMed]

42.

Jani BD, McQueenie R, Nicholl BI, Field R, Hanlon P, Gallacher KI, et al. Association between patterns of alcohol consumption (beverage type, frequency and consumption with food) and risk of adverse health outcomes: a prospective cohort study. BMC Med. 2021;19:8. [DOI] [PubMed] [PMC]

43.

Lampignano L, Donghia R, Sila A, Bortone I, Tatoli R, De Nucci S, et al. Mediterranean diet and fatty liver risk in a population of overweight older Italians: a propensity score-matched case-cohort study. Nutrients. 2022;14:258. [DOI] [PubMed] [PMC]

44.

Simpson RF, Hermon C, Liu B, Green J, Reeves GK, Beral V, et al. Million Women Study Collaborators. Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK Million Women Study. Lancet Public Health. 2019;4:e41–8. [DOI] [PubMed] [PMC]

45.

Namachivayam A, Valsala Gopalakrishnan A. A review on molecular mechanism of alcoholic liver disease. Life Sci. 2021;274:119328. [DOI] [PubMed]

46.

Grønbaek M, Jensen MK, Johansen D, Sørensen TI, Becker U. Intake of beer, wine and spirits and risk of heavy drinking and alcoholic cirrhosis. Biol Res. 2004;37:195–200. [DOI] [PubMed]

47.

Jensen MK, Andersen AT, Sørensen TIA, Becker U, Thorsen T, Grønbaek M. Alcoholic beverage preference and risk of becoming a heavy drinker. Epidemiology. 2002;13:127–32. [DOI] [PubMed]

48.

Koller H, Perkins LB. Brewing and the chemical composition of amine-containing compounds in beer: a review. Foods. 2022;11:257. [DOI] [PubMed] [PMC]

49.

Humia BV, Santos KS, Barbosa AM, Sawata M, Mendonça MdC, Padilha FF. Beer molecules and its sensory and biological properties: a review. Molecules. 2019;24:1568. [DOI] [PubMed] [PMC]

50.

Markoski MM, Garavaglia J, Oliveira A, Olivaes J, Marcadenti A. Molecular properties of red wine compounds and cardiometabolic benefits. Nutr Metab Insights. 2016;9:NMI.S32909. [DOI] [PubMed] [PMC]

51.

Han S, Yang J, Choi K, Kim J, Adhikari K, Lee J. Chemical analysis of commercial white wines and its relationship with consumer acceptability. Foods. 2022;11:603. [DOI] [PubMed] [PMC]

52.

Simonetti P, Cervato G, Brusamolino A, Gatti P, Pellegrini N, Cestaro B. Effect of red wine consumption on rat liver peroxidation. Alcohol. 1996;13:41–5. [DOI] [PubMed]

53.

Cowpland C, Su GM, Murray M, Puddey IB, Croft KD. Effect of alcohol on cytochrome p450 arachidonic acid metabolism and blood pressure in rats and its modulation by red wine polyphenolics. Clin Exp Pharmacol Physiol. 2006;33:183–8. [DOI] [PubMed]

54.

Assunção M, Santos-Marques MJ, Monteiro R, Azevedo I, Andrade JP, Carvalho F, et al. Red wine protects against ethanol-induced oxidative stress in rat liver. J Agric Food Chem. 2009;57:6066–73. [DOI] [PubMed]

55.

Vejarano R, Luján-Corro M. Red wine and health: approaches to improve the phenolic content during winemaking. Front Nutr. 2022;9:890066. [DOI] [PubMed] [PMC]

56.

Romain C, Bresciani L, Gaillet S, Feillet-Coudray C, Calani L, Bonafos B, et al. Moderate chronic administration of Vineatrol-enriched red wines improves metabolic, oxidative, and inflammatory markers in hamsters fed a high-fat diet. Mol Nutr Food Res. 2014;58:1212–25. [DOI] [PubMed]

57.

Izzo C, Annunziata M, Melara G, Sciorio R, Dallio M, Masarone M, et al. The role of resveratrol in liver disease: a comprehensive review from in vitro to clinical trials. Nutrients. 2021;13:933. [DOI] [PubMed] [PMC]

58.

Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El May M, Gharbi N, et al. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci. 2007;80:1033–9. [DOI] [PubMed]

59.

Bujanda L, García-Barcina M, Gutiérrez-de Juan V, Bidaurrazaga J, de Luco MF, Gutiérrez-Stampa M, et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol. 2006;6:35. [DOI] [PubMed] [PMC]

60.

Rocha KKHR, Souza GA, Seiva FRF, Ebaid GX, Novelli ELB. Weekend ethanol consumption and high-sucrose diet: resveratrol effects on energy expenditure, substrate oxidation, lipid profile, oxidative stress and hepatic energy metabolism. Alcohol Alcohol. 2011;46:10–6. [DOI] [PubMed]

61.

Zhang S, Xu Y, Ye M, Ye W, Xiao J, Zhou H, et al. Resveratrol in liquor exacerbates alcoholic liver injury with a reduced therapeutic effect in mice: an unsupervised herbal wine habit is risky. Nutrients. 2022;14:4752. [DOI] [PubMed] [PMC]

62.

Kołota A, Głąbska D, Oczkowski M, Gromadzka-Ostrowska J. Oxidative stress parameters in the liver of growing male rats receiving various alcoholic beverages. Nutrients. 2020;12:158. [DOI] [PubMed] [PMC]

63.

Kołota A, Głąbska D, Oczkowski M, Gromadzka-Ostrowska J. Influence of alcohol consumption on body mass gain and liver antioxidant defense in adolescent growing male rats. Int J Environ Res Public Health. 2019;16:2320. [DOI] [PubMed] [PMC]

64.

Kanuri G, Wagnerberger S, Landmann M, Prigl E, Hellerbrand C, Bischoff SC, et al. Effect of acute beer ingestion on the liver: studies in female mice. Eur J Nutr. 2015;54:465–74. [DOI] [PubMed]

65.

Landmann M, Wagnerberger S, Kanuri G, Ziegenhardt D, Bergheim I. Beer is less harmful for the liver than plain ethanol: studies in male mice using a binge-drinking model. Alcohol Alcohol. 2015;50:493–500. [DOI] [PubMed]

66.

Jung F, Lippmann T, Brandt A, Jin CJ, Engstler AJ, Baumann A. Moderate consumption of fermented alcoholic beverages diminishes diet-induced non-alcoholic fatty liver disease through mechanisms involving hepatic adiponectin signaling in mice. Eur J Nutr. 2020;59:787–99. [DOI] [PubMed] [PMC]

67.

Pinto C, Cestero JJ, Rodríguez-Galdón B, Macías P. Xanthohumol, a prenylated flavonoid from hops (Humulus lupulus L.), protects rat tissues against oxidative damage after acute ethanol administration. Toxicol Rep. 2014;1:726–33. [DOI] [PubMed] [PMC]

68.

Jung F, Staltner R, Baumann A, Burger K, Halilbasic E, Hellerbrand C, et al. A xanthohumol-rich hop extract diminishes endotoxin-induced activation of TLR4 signaling in human peripheral blood mononuclear cells: a study in healthy women. Int J Mol Sci. 2022;23:12702. [DOI] [PubMed] [PMC]

69.

Jung F, Staltner R, Tahir A, Baumann A, Burger K, Halilbasic E, et al. Oral intake of xanthohumol attenuates lipoteichoic acid-induced inflammatory response in human PBMCs. Eur J Nutr. 2022;61:4155–66. [DOI] [PubMed] [PMC]

70.

Jung F, Burger K, Staltner R, Brandt A, Mueller S, Bergheim I. Markers of intestinal permeability are rapidly improved by alcohol withdrawal in patients with alcohol-related liver disease. Nutrients. 2021;13:1659. [DOI] [PubMed] [PMC]

71.

Rodda LN, Gerostamoulos D, Drummer OH. Pharmacokinetics of iso-α-acids in volunteers following the consumption of beer. J Anal Toxicol. 2014;38:354–9. [DOI] [PubMed]

72.

Rodda LN, Gerostamoulos D, Drummer OH. Detection of iso-α-acids to confirm beer consumption in postmortem specimens. Drug Test Anal. 2015;7:65–74. [DOI] [PubMed]

73.

Quifer-Rada P, Martínez-Huélamo M, Chiva-Blanch G, Jáuregui O, Estruch R, Lamuela-Raventós RM. Urinary isoxanthohumol is a specific and accurate biomarker of beer consumptionce1, 2, 3. J Nutr. 2014;144:484–8. [DOI] [PubMed]

74.

Global Burden of Disease Collaborative Network. GBD results [Internet]. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); c2023 [cited 2023 Apr 3]. Available from: https://vizhub.healthdata.org/gbd-results/

75.

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22. Erratum in: Lancet. 2020;396:1562. [DOI] [PubMed] [PMC]

76.

Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: a current molecular and clinical perspective. Liver Res. 2018;2:161–72. [DOI] [PubMed] [PMC]

77.

Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Res Health. 2006;29:245–54.

78.

Bergheim I. 7 Rolle von Darmflora und Darmbarriere in der Entstehung chronischer Lebererkrankungen. In: Bischoff SC, editor. Probiotika, Präbiotika und Synbiotika. Stuttgart: Georg Thieme Verlag KG; 2009. pp. 69–74.

79.

Buiatti S. 20 - Beer composition: an overview. In: Preedy VR, editor. Beer in health and disease prevention. San Diego: Academic Press; 2009. pp. 213–25.

80.

Gutiérrez-Escobar R, Aliaño-González MJ, Cantos-Villar E. Wine polyphenol content and its influence on wine quality and properties: a review. Molecules. 2021;26:718. [DOI] [PubMed] [PMC]

81.

Hovland A, Jonasson L, Garred P, Yndestad A, Aukrust P, Lappegård KT, et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis. 2015;241:480–94. [DOI] [PubMed]